The CHAI platform extracted quantitative histomorphologic features from whole-slide images of hematoxylin and eosin–stained diagnostic biopsies. In a multi-institutional development cohort, features ...
Drug development involves significant risk and expense. With average development costs topping $1 billion per approved medicine and stubbornly high failure rates, pharmaceutical leaders are ...
Every decision in drug development carries weight. The right biomarker insights can make those decisions more confident and data-driven. In this white paper, experts from AstraZeneca, Johnson & ...
Please provide your email address to receive an email when new articles are posted on . ADx NeuroSciences and Alamar Biosciences have announced a partnership to develop customized biomarker assays for ...
Bridging Discovery with Clinical Practice: Biomarkers for Early Detection in Diabetic Kidney Disease
Diabetic kidney disease (DKD) is a major microvascular complication of diabetes and remains the leading cause of end-stage renal disease (ESRD) worldwide.
Aging is a highly individual process. An international consortium coordinated by researchers in Konstanz has developed a ...
We’re in the midst of a paradigm shift in biomarker science. Once considered exploratory, biomarker signatures have evolved into strategic assets - tools that actively de-risk decision-making across ...
Karan Arora, senior vice president of advanced assays, AI, and pharma services at Leica Biosystems outlines the critical role ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results